21.   The benefits of such treatment may be the prevention of relapses of inflammatory bowel disease and the reduction of systemic illness during chronic relapses.

22.   Endoscopy was performed at entry to confirm the diagnosis of inflammatory bowel disease.

23.   With inflammatory bowel disease, the loss of protein through the gastrointestinal tract is also a contributory factor.

24.   Rises in whole body turnover rates have also been seen in patients with inflammatory bowel disease.

25.   Patients with colorectal tumours and inflammatory bowel disease underwent standard bowel preparation which consisted of a low residue diet for two days and picolax on the day before surgery.

26.   Previous investigations of protein metabolism in patients with inflammatory bowel disease, like those in malignancy, have centred on whole body measurements.

27.   The occurrence of a colonic stricture in either form of inflammatory bowel disease raises the question of malignancy.

28.   Seventy seven patients with inflammatory bowel disease were also included in the study.

29.   The role of platelet activating factor blocker in the treatment of inflammatory bowel disease deserves investigation.

30.   Positive cells were found mainly in the subepithelial region in normal colon, while in inflammatory bowel disease they also appeared in the deeper lamina propria.